Company Profile

Ensysce Biosciences Inc
Profile last edited on: 5/16/2023      CAGE: 54Y29      UEI: WRLNV3N149G5

Business Identifier: Abuse-deterrent and overdose technology relavent/ applicable to 75% of all marketed drugs.
Year Founded
2008
First Award
2012
Latest Award
2012
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7946 Ivanhoe Avenue Suite 201
La Jolla, CA 92037
   (858) 263-4196
   info@ensysce.com
   www.ensysce.com
Location: Single
Congr. District: 50
County: San Diego

Public Profile

Ensysce Biosciences (NASDAQ: ENSC) is a clinical-stage biotech company strucrured around development of TWO new classes of Opioids - the first in decades – which protect against abuse and overdose while providing powerful relief for severe and chronic pain. Using the firm's proprietary technology platforms to develop safer prescription drugs, personnel are leveraging its Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™) platforms - developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. With a minimal SBIR presence and that some years ago, the platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : ENSC
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $298,072
Project Title: Optimization of Swcnt/Sirna Complex Formulation for Tumor Accumulation

Key People / Management

  Bob Gower -- CEO and Founder

  Lynn Kirkpatrick -- President and CEO

  Geoff Birkett -- Chief Commercial Officer

  David Humphrey -- Chief Financial Officer

  Kurt Schmidt -- CFO

  William Schmidt -- Chief Medical Officer

  Richard Wright -- Chief Business Officer